Medicare Announces 10 Drugs Targeted for Price Cuts in 2026

People on Medicare may in 2026 see prices drop for 10 medicines, including pricey diabetes, cancer, blood clot, and arthritis treatments, if advocates for federal drug-price negotiations can implement their plans amid tough opposition. The Biden administration revealed the first 10 drugs selected for direct Medicare price negotiations in accordance with a process mandated by the Inflation Reduction Act of 2022. The 10 selected medicines are as follows: Eliquis (generic name: apixaban), Jardiance (generic name: empagliflozin), Xarelto (generic name: rivaroxaban), Januvia (generic name: sitagliptin), Farxiga (generic name: dapagliflozin), Entresto (generic name: sacubitril/valsartan), Enbrel( generic name: etanercept), Imbruvica (generic name: ibrutinib), Stelara (generic name: ustekinumab), Fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill.

Link: Medscape (August 2023)